COMMITMENTS AND CONTINGENCIES The future minimum rental payments for operating leases having initial or remaining non-cancelable lease terms in excess of one year at June 30, 2014 are: (Dollars in millions) 2015 2016 2017 2018 2019 Thereafter Total Minimum rental payments $ 4.6 $ 3.5 $ 3.0 $ 2.7 $ 2.4 $ 6.8 $ 23.0 Rental expense relating to operating leases was approximately $9.5 million , $9.4 million and $13.1 million for the fiscal years ended June 30, 2014 , June 30, 2013 and June 30, 2012 , respectively. Sublease rental income was not material for any period presented herein. Other Matters As previously disclosed with regard to the Company s participation in a multi-employer pension plan, the Company notified the plan trustees of its withdrawal from such plan in fiscal 2012. The withdrawal from the plan resulted in the recognition of liabilities associated with the Company s long term obligations in both the prior and current year periods, which were primarily recorded as an expense within discontinued operations. The actuarial review process, which is administered by the plan trustees, is ongoing and the Company awaits final determination as to the Company s ultimate liability. The annual cash impact associated with the Company s long term obligation approximates $1.7 million per year. Refer to Note 10 to the Consolidated Financial Statements for further discussion. Beginning in November 2006, the Company, along with several pharmaceutical companies, has been named in approximately 380 civil lawsuits. These lawsuits were filed by individuals allegedly injured by their use of the prescription acne medication Amnesteem ® , a branded generic form of isotretinoin, and in some instances, of isotretinoin products made and/or sold by other firms as well. All but one of these lawsuits have been dismissed or settled. The Company was not required to make any contribution toward any settlement to date. While it is not possible to determine the ultimate outcome of this legal proceeding, including making a determination